Day One Biopharmaceuticals (DAWN) Competitors $6.26 -0.03 (-0.40%) As of 11:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. MLTX, IMVT, IBRX, XENE, AMRX, HCM, OGN, MIRM, APLS, and ARWRShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), HUTCHMED (HCM), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. MoonLake Immunotherapeutics Immunovant ImmunityBio Xenon Pharmaceuticals Amneal Pharmaceuticals HUTCHMED Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Arrowhead Pharmaceuticals Day One Biopharmaceuticals (NASDAQ:DAWN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the MarketBeat Community prefer DAWN or MLTX? MoonLake Immunotherapeutics received 16 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 82.76% of users gave MoonLake Immunotherapeutics an outperform vote while only 70.89% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes5670.89% Underperform Votes2329.11% MoonLake ImmunotherapeuticsOutperform Votes7282.76% Underperform Votes1517.24% Which has more risk and volatility, DAWN or MLTX? Day One Biopharmaceuticals has a beta of -1.24, indicating that its stock price is 224% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Do insiders and institutionals have more ownership in DAWN or MLTX? 87.9% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is DAWN or MLTX more profitable? MoonLake Immunotherapeutics' return on equity of -15.54% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% MoonLake Immunotherapeutics N/A -15.54%-15.09% Which has preferable earnings & valuation, DAWN or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Day One Biopharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$161.92M3.94-$188.92M-$0.71-8.86MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-16.76 Do analysts recommend DAWN or MLTX? Day One Biopharmaceuticals currently has a consensus target price of $30.57, suggesting a potential upside of 386.03%. MoonLake Immunotherapeutics has a consensus target price of $78.71, suggesting a potential upside of 104.24%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Day One Biopharmaceuticals is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor DAWN or MLTX? In the previous week, MoonLake Immunotherapeutics had 16 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 11 mentions for Day One Biopharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 1.11 beat Day One Biopharmaceuticals' score of 0.82 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMoonLake Immunotherapeutics beats Day One Biopharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$637.57M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-6.118.9226.8419.71Price / Sales3.94253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.586.466.794.50Net Income-$188.92M$143.98M$3.23B$248.18M7 Day Performance2.11%2.03%1.53%0.20%1 Month Performance-14.19%4.11%10.05%12.37%1 Year Performance-56.98%-2.87%16.71%7.04% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.9065 of 5 stars$6.27-0.4%$30.57+388.0%-57.5%$634.43M$161.92M-6.0860MLTXMoonLake Immunotherapeutics3.2907 of 5 stars$39.20+4.2%$78.71+100.8%-1.3%$2.51BN/A-30.392Positive NewsAnalyst UpgradeGap UpIMVTImmunovant2.7008 of 5 stars$14.70+1.7%$38.33+160.8%-52.4%$2.50BN/A-5.61120Positive NewsGap UpIBRXImmunityBio1.86 of 5 stars$2.80-1.4%$12.19+335.3%-61.1%$2.47B$31.22M-3.04590Analyst UpgradeXENEXenon Pharmaceuticals3.2369 of 5 stars$30.95+2.2%$54.82+77.1%-21.9%$2.37B$7.50M-10.98210Positive NewsAnalyst DowngradeAMRXAmneal Pharmaceuticals3.252 of 5 stars$7.50-1.3%$11.50+53.3%+8.7%$2.35B$2.83B-11.037,600HCMHUTCHMED2.2729 of 5 stars$13.48+0.7%$19.00+40.9%-33.6%$2.35B$630.20M0.001,760Positive NewsAnalyst DowngradeGap DownOGNOrganon & Co.4.7537 of 5 stars$9.00-0.4%$18.00+100.0%-61.3%$2.34B$6.29B2.7010,000MIRMMirum Pharmaceuticals4.0851 of 5 stars$44.89-0.3%$60.73+35.3%+71.8%$2.22B$379.25M-22.22140News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.1775 of 5 stars$17.67+1.3%$40.42+128.8%-59.1%$2.22B$775.84M-8.70770Gap UpARWRArrowhead Pharmaceuticals3.5175 of 5 stars$15.74+0.2%$42.13+167.6%-38.8%$2.17B$545.21M-3.04400News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Immunovant Competitors ImmunityBio Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors HUTCHMED Competitors Organon & Co. Competitors Mirum Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DAWN Stock Free DAWN Stock Alerts